转换艾考恩丙替及联合索磷布韦/维帕他韦治疗慢性丙型肝炎初治的HIV/HCV合并感染者的效果及对血脂水平的影响  

Efficacy of switching to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide combined with sofosbuvir/velpatasvir in treatment of previously untreated chronic hepatitis C patients with HIV/HCV co-infection and its influence on blood lipid levels

作　　者：党便利 康文臻 毕铭辕 李建辉 陈昭云[2] 李姝鹏 刘青 孙永涛 蔡卫平[3] 康文 DANG Bianli;KANG Wenzhen;BI Mingyuan;LI Jianhui;CHEN Zhaoyun;LI Shupeng;LIU Qing;SUN Yongtao;CAI Weiping;KANG Wen(Department of Infectious Diseases,Tangdu Hospital,Air Force Medical University,Xi’an 710038,China;Infecctious Disease Center,The Sixth People’s Hospital of Zhengzhou,Zhengzhou 450015,China;Infectious Disease Center,Guangzhou Eighth People’s Hospital,Guangzhou 510060,China)

机构地区：[1]空军军医大学第二附属医院传染科,西安710038 [2]郑州市第六人民医院感染科,郑州450015 [3]广州市第八人民医院感染科,广州510060

出　　处：《临床肝胆病杂志》2022年第3期541-546,共6页Journal of Clinical Hepatology

基　　金：国家“十三五”科技重大专项项目(2017ZX10202101-003-007,2017ZX10202101-004-005,2017ZX10202203-008-003,2017ZX10202102-002-001)。

摘　　要：目的观察转换艾考恩丙替及联合索磷布韦/维帕他韦治疗慢性丙型肝炎初治的HIV/HCV合并感染者的疗效及血脂水平变化。方法本研究为前瞻性队列研究。纳入2019年7月—2021年5月于空军军医大学第二附属医院传染科就诊的已接受抗逆转录病毒治疗(ART)并获得HIV持续抑制的、慢性丙型肝炎初治的HIV/HCV合并感染患者10例,将原ART方案转换为艾考恩丙替抗HIV治疗共32周,于转换后第4周开始联合索磷布韦/维帕他韦抗HCV治疗12周,监测10例患者转换艾考恩丙替抗HIV治疗及联合索磷布韦/维帕他韦抗HCV治疗前后体质量、BMI、HCV基因型、AFP、肝脏硬度值、CD4+T淋巴细胞(简称CD4细胞)数量、CD4+T/CD8+T(简称CD4/CD8)比值、肝肾功能相关指标、血脂相关指标、HIV RNA、HCV RNA、SVR12、SVR24及不良反应发生。计量资料两组间比较采用Mann-Whitney U检验。相关性分析采用Spearman相关性检验。结果相较于抗HIV治疗基线(原ART方案),10例患者(HCV基因2a和1b型)转换艾考恩丙替治疗4周后,HIV RNA低于检测下限(20 IU/mL),Alb水平下降(Z=-2.801,P=0.0037),其他指标均保持稳定,且患者自我报告原ART方案的抗HIV治疗相关不良事件发生情况明显改善。艾考恩丙替联合索磷布韦/维帕他韦4周后的HCV RNA低于检测下限(15 IU/mL),SVR12和SVR24均达100%;相较于抗HCV治疗基线,治疗12周患者ALT(Z=-2.732,P=0.0048)和AST(Z=-2.501,P=0.0107)均显著下降;而TC(Z=-2.797,P=0.0039)及LDL-C(Z=-2.343,P=0.0185)均较显著回升,且两者呈显著正相关(r=0.87,P<0.001),其他指标均正常。结论转换艾考恩丙替及联合索磷布韦/维帕他韦治疗HCV初治的HIV/HCV合并感染者具有良好的疗效、耐受性和安全性,两药的联合既避免了药物之间相互作用,又可获得极高的HCV治愈率,并维持HIV持续病毒学抑制,联合治疗期间TC及LDL-C水平短暂升高,可能反映了HCV感染导致的脂代谢紊乱及该治疗方案的药理Objective To investigate the efficacy of switching to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide(E/c/F/TAF)combined with sofosbuvir/velpatasvir(SOF/VEL)in the treatment of previously untreated chronic hepatitis C patients with HIV/HCV co-infection and the changes in blood lipid levels.Methods This prospective cohort study was conducted among 10 previously untreated chronic hepatitis C patients with HIV/HCV co-infection who attended Department of Infectious Diseases in Tangdu Hospital from July 2019 to May 2021 and achieved continuous HIV suppression after antiretroviral treatment(ART).As for anti-HIV therapy,the ART regimen was switched to the E/c/F/TAF regimen for 32 weeks,and for anti-HCV therapy,the SOF/VEL regimen was started since week 4 after switching and lasted for 12 weeks.Related indices were monitored before and after switching to E/c/F/TAF for anti-HCV therapy and SOF/VEL for anti-HCV therapy,including body weight,body mass index,HCV genotype,alpha-fetoprotein,liver stiffness measurement,CD4+T cell count,CD4+T/CD8+T ratio,hepatic and renal function parameters,blood lipids,HIV RNA,HCV RNA,SVR12,SVR24,and adverse reactions.The Mann-Whitney U test was used for comparison of continuous data between two groups,and a Spearman correlation analysis was performed.Results After 4 weeks of treatment with E/c/F/TAF,10 patients(HCV genotypes 2a and 1b)had HIV RNA below the lower limit of detection(20 IU/ml)and a significant reduction in albumin(Z=-2.801,P=0.0037),with the other indices remaining stable,and the patients reported significant improvements in the adverse events of anti-HIV therapy with the former ART regimen.After 4 weeks of E/c/F/TAF combined with SOF/VEL,the patients had HCV RNA below the lower limit of detection(15 IU/ml),and both SVR12 and SVR24 reached 100%;after 12 weeks of anti-HCV therapy,there were significant reductions in alanine aminotransferase(Z=-2.732,P=0.0048)and aspartate aminotransferase(Z=-2.501,P=0.0107)and significant increases in total cholesterol(T

关 键 词：肝炎病毒属 HIV感染 抗病毒药 治疗结果 

分 类 号：R51[医药卫生—内科学]